Atlas Trials

Rifaximin for the Treatment of Gastrointestinal Toxicities Related to Pertuzumab-Based Therapy in Patients With Stage I-III HER2 Positive Breast Cancer

Clinical trial NCT04249622 · TERMINATED

Trial details

NCT number
NCT04249622
Sponsor
Mayo Clinic
Status
TERMINATED
Phase
Phase 2
Study type
INTERVENTIONAL
Anatomic Stage I Breast Cancer AJCC v8Anatomic Stage IA Breast Cancer AJCC v8Anatomic Stage IB Breast Cancer AJCC v8Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage IIA Breast Cancer AJCC v8Anatomic Stage IIB Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IIIA Breast Cancer AJCC v8Anatomic Stage IIIB Breast Cancer AJCC v8Anatomic Stage IIIC Breast Cancer AJCC v8HER2 Positive Breast CarcinomaPrognostic Stage I Breast Cancer AJCC v8
Start date
2020-09-18
Primary completion
2022-12-27
Enrollment
20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.